var data={"title":"Memantine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Memantine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6524?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=memantine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Memantine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192478\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Namenda;</li>\n      <li>Namenda Titration Pak;</li>\n      <li>Namenda XR;</li>\n      <li>Namenda XR Titration Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F554085\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ebixa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192491\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        N-Methyl-D-Aspartate Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192480\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alzheimer disease, moderate to severe: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial: 5 mg daily; increase dose by 5 mg daily (if previous dose well tolerated) to a target dose of 20 mg daily; wait &ge;1 week between dosage changes. Doses &gt;5 mg daily should be given in 2 divided doses. <b>Note:</b> If treatment is interrupted for longer than several days, the treatment may need to be restarted at a lower dose and retitrated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suggested titration: 5 mg daily for &ge;1 week; 5 mg twice daily for &ge;1 week; 15 mg daily given in 5 mg and 10 mg separate doses for &ge;1 week; then 10 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Initial: 7 mg once daily, increase dose by 7 mg daily to a target maximum dose of 28 mg once daily; wait &ge;1 week between dosage changes (if previous dose well tolerated)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> When switching from immediate release product to the extended release product, begin the extended release product the day after the last dose of the immediate release product. Patients on immediate release 10 mg twice daily should be switched to extended release 28 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed dose:</i> If a single dose is missed, do not double up on the next dose; take the next dose as scheduled. If several days of dosing are missed, dosing may need to be resumed at lower doses and retitrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vascular dementia, mild to moderate (off-label use):</b> Oral: Immediate release: Initial: 5 mg once daily; titrate in increments of 5 mg daily each week to a target dose of 10 mg twice daily (Orgogozo, 2002; Wilcock 2002). Additional data may be necessary to further define the role of memantine in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192481\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192482\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> (CrCl 30 to 49 mL/minute): Initial: 5 mg once daily; after at least 1 week of therapy and if tolerated, titrate up to 5 mg twice daily; based on clinical response and tolerability, may further titrate dosage upward in weekly increments to 20 mg daily according to suggested titration schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> CrCl 5 to 29 mL/minute: Immediate release: Initial: 5 mg once daily; after at least 1 week of therapy and if tolerated, may titrate up to a target dose of 5 mg twice daily; Extended release: Target dose of 14 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> When switching from immediate release product to the extended release product, begin the extended release product the day after the last dose of the immediate release product. Patients on immediate release 5 mg twice daily should be switched to extended release 14 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> CrCl 15 to 29 mL/minute: Initial: 5 mg once daily; after at least 1 week of therapy and if tolerated, may titrate up to a target dose of 5 mg twice daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10450024\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>U.S. labeling:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Canadian labeling:</i> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192458\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Namenda XR: 7 mg, 14 mg, 21 mg, 28 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Namenda XR Titration Pack: 7 mg (7s) and 14 mg (7s) and 21 mg (7s) and 28 mg (7s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 7 mg, 14 mg, 21 mg, 28 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Namenda: 10 mg/5 mL (360 mL [DSC]) [peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (360 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Namenda: 5 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Namenda: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Namenda Titration Pak: 5 mg (28s) and 10 mg (21s) [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 5 mg (28s) and 10 mg (21s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192447\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10450025\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer without regard to meals. Extended release capsules may be swallowed whole or entire contents of capsule may be sprinkled on applesauce and swallowed immediately; do not chew, crush, or divide. Withdraw and administer oral solution with provided dosing device; dose should be slowly squirted into the corner of the patient&rsquo;s mouth. Do not mix oral solution with any other liquid. The Canadian labeling recommends tablets to be swallowed whole with water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192460\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Alzheimer disease:</b> Treatment of moderate to severe dementia of the Alzheimer type.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730710\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Vascular dementia (mild to moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7828224\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Memantine may be confused with mesalamine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192451\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions similar in immediate and extended release formulations except as noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (4%), hypotension (extended release: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (5% to 7%), confusion (6%), headache (6%), anxiety (extended release: 4%), depression (extended release: 3%), drowsiness (3%), hallucination (3%), pain (3%), aggressive behavior (2%), fatigue (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Weight gain (extended release: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (5%), constipation (3% to 5%), vomiting (2% to 3%), abdominal pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary incontinence (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Influenza (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (4%), dyspnea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal gait, abnormal hepatic function tests, acne vulgaris, agitation, agranulocytosis, anorexia, arthralgia, aspiration pneumonia, atrioventricular block, bone fracture, bradycardia, brain disease, bronchitis, cardiac failure, carpal tunnel syndrome, cerebral infarction, cerebrovascular accident, chest pain, cholelithiasis, claudication, colitis, coma, complete atrioventricular block, convulsions, decreased appetite, deep vein thrombosis, dehydration, delusions, dementia (Alzheimer type), disorientation, drug-induced Parkinson disease, dyskinesia, falling, fecal incontinence, fever, gastritis, gastroesophageal reflux disease, hepatic failure, hepatitis (including cytolytic and cholestatic), hyperglycemia, hyperlipidemia, hypoglycemia, impaired consciousness, impotence, increased INR, increased serum alkaline phosphatase, increased serum creatinine, insomnia, intracranial hemorrhage, irritability, lethargy, leukopenia, limb pain, loss of consciousness, malaise, myoclonus, nasopharyngitis, nausea, neuroleptic malignant syndrome, neutropenia, otitis media, pancreatitis, pancytopenia, peripheral edema, prolonged Q-T interval on ECG, psychotic reaction, renal failure, renal function test abnormality, renal insufficiency, restlessness, second degree atrioventricular block, sepsis, SIADH, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, supraventricular tachycardia, tardive dyskinesia, thrombocytopenia, thrombotic thrombocytopenic purpura, tonic-clonic seizures, torsades de pointes, tremor, upper respiratory tract infection, urinary tract infection, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192463\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to memantine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192449\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Rare skin hypersensitivity reactions (eg, Stevens Johnson syndrome, erythema multiforme) have been reported; advise patients to report skin reactions immediately. Discontinue use with signs of hypersensitivity reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; although adverse cardiac events were infrequent in clinical trials, an increased incidence of cardiac failure, angina, bradycardia, and hypertension (compared with placebo) was observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment. The Canadian labeling recommends avoiding use in severe impairment due to a lack of data in this population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic disease: Worsening of corneal condition has been observed in a clinical trial; periodic ophthalmic exams during use are recommended (Canadian labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; dose adjustments for CrCl &lt;30 mL/minute is required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urine pH: Clearance is significantly reduced by alkaline urine; use caution with medications, dietary changes, or patient conditions which may alter urine pH.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299660\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192453\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10131&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alkalinizing Agents: May increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: Memantine may diminish the therapeutic effect of Benperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Memantine.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NMDA Receptor Antagonists: May enhance the adverse/toxic effect of Memantine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine. Memantine may increase the serum concentration of Trimethoprim.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192455\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192466\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616135\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if memantine is excreted in breast milk. The US labeling recommends that caution be exercised when administering memantine to nursing women. The Canadian labeling recommends avoiding use in nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11413651\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cognitive function; functional outcomes (eg, Activities of Daily Living [ADLs], Instrumental Activities of Daily Living [IADLs]); periodic ophthalmic exam (Canadian labeling)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192448\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Glutamate, the primary excitatory amino acid in the CNS, may contribute to the pathogenesis of Alzheimer's disease (AD) by overstimulating various glutamate receptors leading to excitotoxicity and neuronal cell death. Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) type of glutamate receptors, located ubiquitously throughout the brain. Under normal physiologic conditions, the (unstimulated) NMDA receptor ion channel is blocked by magnesium ions, which are displaced after agonist-induced depolarization. Pathologic or excessive receptor activation, as postulated to occur during AD, prevents magnesium from reentering and blocking the channel pore resulting in a chronically open state and excessive calcium influx. Memantine binds to the intra-pore magnesium site, but with longer dwell time, and thus functions as an effective receptor blocker only under conditions of excessive stimulation; memantine does not affect normal neurotransmission. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192462\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 9 to 11 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 45% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic, primarily independent of the CYP enzyme system; forms 3 metabolites (minimal activity) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~60 to 80 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: 3 to 7 hours; Extended release: 9 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (74%; ~48% of the total dose as unchanged drug; undergoes active tubular secretion moderated by pH-dependent tubular reabsorption; excretion reduced by alkaline urine pH) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192465\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Memantine HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7 mg (30): $457.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">14 mg (30): $457.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21 mg (30): $457.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">28 mg (30): $457.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Namenda XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7 mg (30): $509.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">14 mg (30): $509.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21 mg (30): $509.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">28 mg (30): $509.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Namenda XR Titration Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7 &amp; 14 &amp; 21 &amp;28 mg (28): $475.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Memantine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (360 mL): $634.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Memantine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $365.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 (28)-10 (21) mg (49): $298.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $365.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Namenda Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $533.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $533.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Namenda Titration Pak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 (28)-10 (21) mg (49): $435.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192468\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abixa (BD, PH);</li>\n      <li>Abixsa (UA);</li>\n      <li>Admed (KR);</li>\n      <li>Admenta (IN);</li>\n      <li>Akatinol (CO, CR, CU, DO, GT, HN, NI, PA, PY, SV, UY);</li>\n      <li>Albix (HK, KR);</li>\n      <li>Amint-10 (PH);</li>\n      <li>Axura (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, PL, PT, RO, RU, SE, SK, TR);</li>\n      <li>Carrier (PY);</li>\n      <li>Cordure (CO);</li>\n      <li>Dementa (BD);</li>\n      <li>Denigma (PH);</li>\n      <li>Ebix (BR);</li>\n      <li>Ebixa (AE, AR, AT, AU, BE, BG, BH, CH, CL, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JO, KR, KW, LB, LT, LU, MT, MX, MY, NL, NO, NZ, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW);</li>\n      <li>Esmirtal (PE);</li>\n      <li>Eutebrol (CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Evy (TW);</li>\n      <li>Foliant (LK);</li>\n      <li>Limember (PE);</li>\n      <li>Lindex (EC);</li>\n      <li>Manotin (TW);</li>\n      <li>Marixino (AT, CZ, IE, LV, MT, SG);</li>\n      <li>Meksiya (UA);</li>\n      <li>Memanto (KR);</li>\n      <li>Memanxa (AU);</li>\n      <li>Memary (JP);</li>\n      <li>Memogen (BD);</li>\n      <li>Memoks (UA);</li>\n      <li>Memoril (NZ);</li>\n      <li>Memox (IL);</li>\n      <li>Memry (PH);</li>\n      <li>Memxa (TH);</li>\n      <li>Mentra (PH);</li>\n      <li>Nemdatine (AT, CZ, IE, LV, SG);</li>\n      <li>Neumantine (TH);</li>\n      <li>Neuroplus (EC);</li>\n      <li>Remtin (BD);</li>\n      <li>Tabixa (QA);</li>\n      <li>Vilimen (TR);</li>\n      <li>Witgen (TW);</li>\n      <li>Ymana (HR);</li>\n      <li>Zimerz (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ballard C, Thomas A, Gerry S, et al. MAIN-AD investigators. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in peoplewith Alzheimer's disease (MAIN-AD). <i>J Am Med Dir Assoc. </i>2015;16(4):316-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/25523285/pubmed\" target=\"_blank\" id=\"25523285\">25523285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. <i>J Alzheimers Dis.</i> 2013;35(2):349-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/23411693/pubmed\" target=\"_blank\" id=\"23411693\">23411693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ebixa (memantine) [product monograph]. Montreal, Quebec, Canada: Lundbeck Canada Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. <i>PLoS One.</i> 2012;7(5):e35185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/22567095/pubmed\" target=\"_blank\" id=\"22567095\">22567095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hort J, O'Brien JT, Gainotti G, et al, &ldquo;EFNS Guidelines for the Diagnosis and Management of Alzheimer&rsquo;s Disease,&rdquo; <i>Eur J Neurol</i>, 2010, 17(10):1236-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/20831773/pubmed\" target=\"_blank\" id=\"20831773\">20831773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kavirajan H; Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. <i>Lancet Neurol</i>. 2007;6(9):782-792.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/17689146/pubmed\" target=\"_blank\" id=\"17689146\">17689146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipton, SA, &ldquo;Failures and Successes of NMDA Receptor Antagonists: Molecular Basis for the Use of Open-Channel Blockers like Memantine in the Treatment of Acute and Chronic Neurologic Insults,&rdquo; <i>NeuroRx</i>, 2004, 1(1):101-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/15717010/pubmed\" target=\"_blank\" id=\"15717010\">15717010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia.<i>Cochrane Database Syst Rev</i>. 2006;(2):CD003154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/16625572/pubmed\" target=\"_blank\" id=\"16625572\">16625572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namenda XR (memantine) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orgogozo JM, Rigaud AS, Stoffler A, M&ouml;bius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). <i>Stroke</i>. 2002;33(7):1834-1839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/12105362/pubmed\" target=\"_blank\" id=\"12105362\">12105362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(12 Suppl):5-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/18340692/pubmed\" target=\"_blank\" id=\"18340692\">18340692</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. Guideline watch (October 2014): Practice guideline for the treatment of patients with Alzheimer&rsquo;s disease and other dementias. American Psychiatric Association; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reisberg B, Doody R, Stoffler A, et al, &ldquo;Memantine in Moderate-to-Severe Alzheimer's Disease,&rdquo; <i>N Engl J Med</i>, 2003, 348(14):1333-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/12672860/pubmed\" target=\"_blank\" id=\"12672860\">12672860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tariot PN, Farlow MR, Grossberg GT, et al, &ldquo;Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial. The Memantine Study Group,&rdquo; <i>JAMA</i>, 2004, 291(3):317-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/14734594/pubmed\" target=\"_blank\" id=\"14734594\">14734594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). <i>Int Clin Psychopharmacol</i>. 2002;17(6):297-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/memantine-drug-information/abstract-text/12409683/pubmed\" target=\"_blank\" id=\"12409683\">12409683</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10131 Version 188.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192478\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F554085\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F192491\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F192480\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F192481\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F192482\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10450024\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192458\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F192447\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10450025\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F192460\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730710\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7828224\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192451\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192463\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192449\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299660\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F192453\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192455\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F192466\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616135\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11413651\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192448\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F192462\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F192465\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F192468\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10131|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=memantine-patient-drug-information\" class=\"drug drug_patient\">Memantine: Patient drug information</a></li></ul></div></div>","javascript":null}